Novartis’ Oral Multiple Sclerosis Drug Meets Main Goal in Late Stage Studies - Regional Media News

Novartis' oral multiple sclerosis drug meets main goal in late stage studies

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Ad hoc announcement pursuant to Art. 53 LR

Novartis (NVS) Stock Surges 5% Following Positive Multiple Sclerosis Drug Trial Results

Key Takeaways Shares of Novartis climbed approximately 5% following positive Phase 3 trial outcomes for remibrutinib, an oral multiple sclerosis treatment The experimental drug outperformed teriflunomide (marketed as Aubagio by Sanofi) in decreasing relapse frequency among relapsing MS patients Remibrutinib demonstrated significant benefits in reducing disability progression without raising hepatic safety flags The pharmaceutical giant suspende…

Novartis (NVS) Stock Jumps 5% as MS Drug Delivers the Goods in Phase 3 Trials

TLDR Novartis stock rose nearly 5% after its oral MS drug remibrutinib met the main goals of two late-stage trials Remibrutinib beat teriflunomide (Sanofi’s Aubagio) in reducing relapse rates in relapsing multiple sclerosis patients The drug also showed meaningful improvement in slowing disability...

Novartis Reports Positive Phase III Results for Oral BTK Inhibitor Remibrutinib in Relapsing Multiple Sclerosis

(IN BRIEF) Novartis has announced positive topline Phase III results from the REMODEL-1 and REMODEL-2 trials of remibrutinib, a highly selective and potent oral BTK inhibitor, in adults with relapsing multiple sclerosis (RMS). The trials met their primary endpoint by … Read the full press release →